The effects of adjuvant Tualang honey therapy on disease activity markers in systemic lupus erythematosus patients

A prospective, unblinded, randomised study to evaluate the effect of adjuvant Tualang honey therapy on disease activity markers in systemic lupus erythematosus patients

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12611000074998

Enrollment

Registered

2011-01-20

Start date

2009-10-19

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

To compare the effects of adjuvant honey therapy versus conventional immunosuppressive therapy alone on disease activity based on disease activity index ( SLEDAI ) score, complement level, ANA and dsDNA in systemic lupus erytematosis patients

Interventions

Oral Tualang honey 20 gm twice a day Duration 6 months

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Open (masking not used)

Eligibility

Sex/Gender

All

Age

13 Years to No maximum

Healthy volunteers

Inclusion criteria

SLE patients fulfilled 4 out of 11 ARA criteria on low dose prednisolone alone or combination with other immunosuppressive drugs and / or either cyclophosphomide or azathioprine maintenance treatment

Exclusion criteria

patients who were diabetic, pregnant, suffering from chronic renal failure, cancer, HIV and allergic to honey

Outcome results